GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
November 28 2022 - 10:15AM
via NewMediaWire --
GeoVax Labs, Inc.
(Nasdaq: GOVX), a biotechnology company developing vaccines and
immunotherapies against infectious diseases and cancers, today
announced that Mark J. Newman, Ph.D., Chief Scientific Officer of
GeoVax, will present at the World Vaccine & Immunotherapy
Congress (WVIC) West Coast 2022, taking place November 28-December
1, 2022, in San Diego, California.
Dr. Newman will discuss the design and evaluation
of MVA-vectored vaccines against betacoronaviruses and GeoVax’s
progress toward producing vaccines that are more potent, induce
broader immune responses, function in immunocompromised patients
and individuals underserved by existing vaccines and are effective
against all COVID-19 variants. He will also discuss GeoVax’s
COVID-19 vaccine, GEO-CM04S1, which is currently in two Phase 2
clinical trials, one as a more potent primary vaccine for
immunocompromised patients and the other trial as a booster vaccine
for healthy patients who have previously received an mRNA
vaccine.
Details of the presentation are as follows:
Title: SARS-CoV-2 Vaccine design to broaden
effector immune responsesSession: ID VaccinesDate and Time:
Tuesday, November 29, 2:50 p.m. PTLocation: Loews Coronado Bay
Resort, San Diego, California
For more information about the WVIC, please visit
the event webpage here.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and
vaccines for cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in two
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
single-dose, COVID-19 vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical
trial evaluating the vaccine as a more robust, durable COVID-19
booster among healthy patients who previously received the mRNA
vaccines. GeoVax has a leadership team who have driven significant
value creation across multiple life science companies over the past
several decades. For more information, visit our
website: www.geovax.com.
For additional information about GeoVax, visit our
website: www.geovax.com.
Media Relations
Contact: Gina
Cestari 6
Degrees 917-797-7904 gcestari@6degreespr.com
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2024 to Oct 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Oct 2023 to Oct 2024